Boston Scientific Corp. (NYSE:BSX) and St. Jude Medical Inc. (NYSE:STJ) released details on a pair of clinical trials, one for implantable cardiac defibrillators and another for transcatheter aortic valves.
The scientists conducting the BSX-funded study, who published their work in the journal Circulation, found that one life is saved for every eight patients who receive an ICD and that there is a 34 percent "relative reduction in the risk of death" for ICD patients at eight years.